Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Discover how Anneo Biotech is quietly leading India's probiotic revolution, building the future of preventive healthcare.

Singapore’s Foreign Minister Vivian Balakrishnan said Wednesday that rising tensions in the Strait of Hormuz could serve as a ...

Nepal is about to miss the train of the biodigital revolution sweeping across the Global South. We cannot afford to sit back ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

Massachusetts biopharma companies report that 90% of firms struggle to fill senior roles. A new leadership initiative aims to ...

Revolution Medicines has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...

Union Minister Jitendra Singh emphasizes the shift towards a circular economy, highlighting how waste is transforming into ...

We recently published Jim Cramer Discussed AI “Mojo” & Commented On These 13 Stocks. Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the stocks discussed by Jim Cramer. Revolution Medicines, Inc.